Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: ePoster: IBD 1 (Sun8)

EP305 - Status of Role of Microbiota and Fecal Microbiota Transplantation in Crohn’s Disease

Sunday, May 11, 2025
9:22 AM – 9:27 AM PT
Location: Monitor 6, Sails Pavilion, Upper Level

    ePoster Presenter(s)

  • Jai Singh, MD

    Colorectal Surgery Fellow
    Henry Ford Providence Hospital
    Rochester Hills, Michigan, United States

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Author(s)

  • MA

    Maryam Aleissa, MBBS (she/her/hers)

    colorectal surgery fellow
    Henry Ford providence hospital
    Michigan State University College of Human Medicine
    southfild, Michigan, United States

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

  • Micheal C. Luca, MD (he/him/his)

    General Surgery Resident
    Ascension Providence Hospital system
    Novi, Michigan, United States

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

  • ED

    Ernesto R. Drelichman, MD

    Colorectal surgeon
    Henry Ford providence Hospital
    Southfield, Michigan, United States

    Disclosure information not submitted.

  • VM

    Vijay k. Mittal, MD

    Hepatobiliary surgeon
    Henry Ford Providence Hospital
    southfild, Michigan, United States

    Disclosure information not submitted.

    • Senior Author(s)

  • Jasneet S. Bhullar, MD, MS, FACS, FASCRS.

    Clinical Associate Professor of Surgery MSU/CHM, Program Director Colorectal Surgery Fellowship MSU
    Henry Ford Providence Hospital
    Ascension - MSU Colorectal Surgery Fellowship, MI
    Rochester Hills, Michigan, United States

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

All of the relevant financial relationships listed below have been mitigated.
Jai Singh, MD: This individual has no financial relationships with ineligible companies.
Maryam Aleissa, MBBS: This individual has no financial relationships with ineligible companies.
Micheal C. Luca, MD: This individual has no financial relationships with ineligible companies.
Jasneet S. Bhullar, MD, MS, FACS, FASCRS.: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background: Crohn’s disease (CD) is an idiopathic, chronic, and recurrent inflammatory condition of the gastrointestinal tract. Recent studies have highlighted the potential role of gut microbiota in CD, particularly the phenomenon of dysbiosis—an imbalance in gut bacteria. While dysbiosis is consistently observed in CD, it remains uncertain whether it is a cause or a consequence of the disease. Given the association of dysbiosis with CD, the therapeutic potential of fecal microbiota transplantation (FMT) has been explored.

Methods/Interventions: A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the PubMed database to identify all relevant studies published between October 2014 and October 2024. Our inclusion criteria were randomized controlled trials, observational studies, and clinical trials related to microbiota and Crohn’s disease, written in English. Data from the selected studies were extracted and analyzed.

Results/Outcomes: An initial literature search yielded 45 articles, but only 6 met the inclusion and exclusion criteria. Among these, only one randomized controlled trial (RCT) compared fecal microbiota transplantation (FMT) with a sham transplantation in Crohn’s disease. Another RCT examined the difference in Crohn’s disease improvement based on the route of FMT administration, comparing esophagogastroduodenoscopy (EGD) with colonoscopy. In this study, all patients received FMT, and there was no control group. The remaining four articles were clinical trials, none of which included a control group.
Response was assessed through improvement in clinical symptoms and clinical remission, including steroid-free remission. The rate of clinical remission ranged from 55% to 87.5%. However, long-term follow-up of the patients who achieved 87.5% remission at 10 weeks showed that the remission rate dropped to 50% after 24 weeks. Improvement in clinical symptoms ranged from 68% to 76%. One study compared fresh FMT with frozen FMT and found that fresh FMT produced better outcomes. The study that examined different routes of FMT administration did not reveal any changes in the outcomes.

Conclusion/Discussion: The current status highlights the potential role of gut microbiota and dysbiosis in CD, indicating that interventions like fecal microbiota transplantation (FMT) merit further study. Given the observed improvements in clinical symptoms and varying remission rates, further research is essential to clarify dysbiosis's role in CD and optimize FMT protocols for improved patient outcomes.